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introduction: Plasma factor VIII (FVIII) and von Willebrand factor (VWF) levels have been 
associated with the rate and severity of arterial thrombus formation and have been linked 
to outcomes following thrombolytic therapy in acute myocardial infarction patients. Here, 
we aimed to investigate FVIII and VWF levels during the course of thrombolysis in acute 
ischemic stroke (AIS) patients and to find out whether they predict long-term outcomes.
Materials and methods: Study population included 131 consecutive AIS patients 
(median age: 69 years, 60.3% men) who underwent i.v. thrombolysis with recombinant 
tissue plasminogen activator (rt-PA). Blood samples were taken on admission, 1 and 24 h 
after rt-PA administration to measure FVIII activity and VWF antigen levels. Neurological 
deficit of patients was determined according to the National Institutes of Health Stroke 
Scale (NIHSS). ASPECT scores were assessed using computer tomography images 
taken before and 24 h after thrombolysis. Intracranial hemorrhage was classified accord-
ing to the European Cooperative Acute Stroke Study (ECASS) II criteria. Long-term 
functional outcome was determined at 90 days after the event by the modified Rankin 
scale (mRS).
results: VWF levels on admission were significantly elevated in case of more severe 
AIS [median and IQR values: NIHSS <6:189.6% (151.9–233.2%); NIHSS 6–16: 199.6% 
(176.4–250.8%); NIHSS >16: 247.8% (199.9–353.8%), p =  0.013]; similar, but non- 
significant trend was observed for FVIII levels. FVIII and VWF levels correlated well on 
admission (r = 0.748, p < 0.001) but no significant correlation was found immediately 
after thrombolysis (r =  0.093, p =  0.299), most probably due to plasmin-mediated 
FVIII degradation. VWF levels at all investigated occasions and FVIII activity before and 
24 h after thrombolysis were associated with worse 24 h post-lysis ASPECT scores. 
In a binary backward logistic regression analysis including age, gender, high-sensitivity 
C-reactive protein, active smoking, diabetes, and NIHSS >5 on admission, elevated FVIII 
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and VWF levels after thrombolysis were independently associated with poor functional 
outcomes (mRS ≥ 3) at 90 days (immediately after thrombolysis: FVIII: OR: 7.10, 95% 
CI: 1.77–28.38, p = 0.006, VWF: OR: 6.31, 95% CI: 1.83–21.73, p = 0.003; 24 h after 
thrombolysis: FVIII: OR: 4.67, 95% CI: 1.42–15.38, p = 0.011, VWF: OR: 19.02, 95% 
CI: 1.94–186.99, p = 0.012).
conclusion: Elevated FVIII activity and VWF antigen levels immediately after lysis and 
at 24 h post-therapy were shown to have independent prognostic values regarding poor 
functional outcomes at 90 days.
Keywords: acute ischemic stroke, intracerebral hemorrhage, factor Viii, therapy outcome, thrombolysis, 
von Willebrand factor
inTrODUcTiOn
Stroke is the second leading cause of death worldwide and the 
most common cause of disability (1). Currently, intravenous 
administration of recombinant tissue plasminogen activator 
(rt-PA), initiated within 4.5 h after symptom onset, is the standard 
therapy for the treatment of acute ischemic stroke (AIS). Although 
thrombolysis using rt-PA treatment has been proven to be safe 
and effective by a number of clinical trials and systematic reviews 
(2, 3), only approximately half of treated patients achieve functional 
independence with complete or nearly complete neurological 
recovery at 3 months (4). Of all thrombolysis-related complica-
tions, the most feared is symptomatic intracerebral hemorrhage, 
which occurs in approximately 7% of patients causing significant 
morbidity and mortality (5, 6). Several factors have been asso-
ciated with a potentially increased risk of poor outcome after 
rt-PA treatment (e.g., advanced age, male gender, stroke severity, 
diabetes, baseline hyperglycemia, etc.) (5), still, clinical outcomes 
are not easily foreseen at the initiation of the therapy as most of 
the current clinical–radiological risk scores are non-specific and 
have modest predictive value (6). In order to improve patient care 
in the near future, new risk prediction models incorporating the 
use of specific biomarkers might be helpful. A potentially useful 
biomarker in this case is expected to be involved in the underlying 
pathophysiological pathway and must confer significant predic-
tive value regarding therapy outcomes.
A growing body of research has demonstrated a role for coagu-
lation factor VIII (FVIII) and von Willebrand factor (VWF) in 
the pathophysiology of AIS (7, 8). FVIII is stabilized in the circu-
lation by VWF: the linear relationship between the levels of FVIII 
and VWF has been described (9). The FVIII–VWF complex plays 
an important role in the propagation of thrombus formation as 
it mediates platelet attachment to the damaged subendothelium 
and supports the activation of coagulation cascade at the site of 
the growing thrombus (7). Plasma FVIII/VWF levels have been 
directly linked to the rate and severity of arterial thrombus for-
mation (10). Elevated levels of FVIII/VWF have been associated 
with the risk of stroke (8, 11, 12); however, less evidence is avail-
able on the prognostic value of both markers in stroke outcomes 
(12, 13). Only few papers, including relatively small cohort of 
patients describe a potential relationship between FVIII and/or 
VWF levels and thrombolysis outcomes (14). Elevated levels of 
VWF during thrombolysis in acute myocardial infarction (AMI) 
patients have been associated with poor recanalization and worse 
outcomes (15). Less is known about the levels of FVIII and VWF 
during the course of thrombolysis in AIS patients—even though 
it has been speculated based on animal studies that the degrada-
tion of FVIII during thrombolysis treatment could be a potential 
causative factor for bleeding complications occurring in treated 
patients (16).
In the past decades, inhibition of the action of VWF has 
become an attractive new antithrombotic strategy in ischemic 
stroke management (7, 17). When used in combination with 
rt-PA, VWF antagonists could promote the rapid dissolution of 
the occluding thrombus and limit subsequent thrombo-inflam-
matory ischemia/reperfusion injury (17). As most of these studies 
were performed in animal models, data regarding the changes of 
VWF/FVIII levels during thrombolysis in humans could be of 
particular interest.
Here, we hypothesized that levels of FVIII and VWF are related 
to stroke severity and/or patient outcome following thrombolysis 
treatment. In this observational study, we investigated the levels 
of FVIII and VWF in a cohort of consecutive AIS patients using 
blood samples taken on three occasions during the course of 
i.v. thrombolysis and assessed the potential prognostic value 
of the measured parameters on functional outcomes at 90 days 
post-event.
MaTerials anD MeThODs
Patients
Consecutive AIS patients aged 18  years or more, eligible for 
thrombolysis, admitted to a single Stroke Center (Department 
of Neurology, Faculty of Medicine, University of Debrecen, 
Hungary) were enrolled in the study. All patients were within 4.5 h 
of their symptom onset at the time of admission. Patient enroll-
ment lasted for 22 months starting in March 2011. Intravenous 
thrombolytic therapy was applied according to the European 
Stroke Organization (ESO) guidelines using rt-PA (Alteplase, 
Boehringer Ingelheim, Germany) (18). Inclusion and exclusion 
criteria of patients were identical to that of thrombolysis eligibil-
ity as described in the ESO 2008 guideline (18). The diagnosis 
of IS was based on clinical symptoms and brain imaging using 
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computer tomography (CT) scan and CT angiography (CTA). 
Admission CTA was used to identify the level of vessel occlusion 
in every patient. A control CT was performed for every patient 
24  h after thrombolysis. All CT images were analyzed by four 
different investigators blinded to the clinical state of the patients 
and the Alberta Stroke Program Early CT Scores (ASPECTS) were 
calculated (19). Neurological deficit of patients was determined 
by the NIHSS (20) at various time points: on admission and at 
2 h, 24 h, and 7 days post-lysis. Stroke etiology was determined 
according to the Trial of ORG 10172 in Acute Stroke Treatment 
(TOAST) criteria (21). Hemorrhagic events were classified as 
symptomatic or asymptomatic intracranial hemorrhage (SICH or 
aSICH, respectively) according to the European Cooperative Acute 
Stroke Study (ECASS) II criteria (22). For each patient a detailed 
list of clinical parameters was recorded including demographic 
characteristics, neurological status, time of symptom onset, car-
diovascular risk factors (arterial hypertension, atrial fibrillation, 
hyperlipidemia, diabetes mellitus, smoking status), history of 
previous cardiovascular events, and medications. Patients were 
followed and long-term functional outcomes were determined at 
90 days post-event using the modified Rankin Scale (mRS) (23).
The following outcomes were investigated: (1) short-term 
functional outcome at 7 days post-event: favorable outcome was 
defined as a decrease in NIHSS score by at least 4 points or to 0 by 
day 7, unfavorable outcome was defined as an increase in NIHSS 
score by at least 4 points by day 7. (2) The presence of therapy-
associated SICH or aSICH was defined according to ECASS II 
criteria. (3) Long-term functional outcome at 90 days post-event: 
poor long-term outcome was specified as an mRS greater than 2.
The study was approved by the Ethics Committee of the 
University of Debrecen, Hungary. All patients or their relatives 
provided written informed consent.
Blood sampling and laboratory 
Measurements
Peripheral blood samples were drawn from patients into vacu-
tainer tubes on three different occasions: upon hospital admis-
sion (before thrombolysis), immediately after the administration 
of rt-PA infusion (~1 h after the initiation of thrombolysis) and 
approximately 24  h after the administration of thrombolytic 
therapy. Routine laboratory tests were performed from blood 
samples taken before thrombolysis and included the measure-
ments of complete blood count, serum ions, glucose levels, 
basic kidney function tests, liver function test, high-sensitivity 
C-reactive protein (hsCRP), and screening tests of coagulation 
(prothrombin time, activated partial thromboplastin time and 
thrombin time). Blood samples anticoagulated with sodium cit-
rate, theophylline, adenosine and dipyridamole (Vacuette CTAD 
Tubes, Greiner Bio-One, Austria) were centrifuged at 1,220  g, 
room temperature for 15 min. Plasma aliquots were labeled with 
a code and stored at −70°C until further analysis of FVIII activity 
and VWF antigen levels. FVIII activity, determined by chromog-
enic method and VWF antigen level, determined by immunotur-
bidimetric assay were measured from coded plasma samples on 
a BCS coagulometer by standard methods (Siemens Healthcare 
Diagnostic Products, Marburg, Germany), by an investigator 
blinded to patient identification and clinical information. Batches 
of plasma samples (approximately 20 samples) were thawed for 
10 min at 37°C followed by immediate analysis. According to the 
manufacturer, precision of the assays are the following: coefficient 
of variation within run (intra-assay precision) for FVIII activity 
assay: 4–9%, for VWF antigen level test: 1.4–4.2%; between run 
(inter-assay precision) for FVIII activity assay: 4–10%, for VWF 
antigen level test: 0.9–2.6%.
statistical analysis
Statistical analysis was performed using the Statistical Package 
for Social Sciences (SPSS, Release 22.0, Chicago, IL, USA) and 
GraphPad Prism 5.0 (GraphPad Prism Inc., La Jolla, CA, USA) 
softwares. Normality of the data was evaluated by the Shapiro–
Wilk test. As FVIII activity and VWF antigen levels were not 
normally distributed at any time points measured, the Mann–
Whitney U test was applied for all two-group analyses and the 
Kruskal–Wallis analysis with Dunn–Bonferroni post hoc test was 
used for multiple comparisons. Differences between categorical 
variables were assessed by the Fisher’s exact or χ2 test. Friedman’s 
two-way ANOVA with Dunn–Bonferroni post hoc test was applied 
to investigate the effect of thrombolysis on FVIII activity and 
VWF levels. Strength of association between FVIII activity and 
VWF antigen levels was tested using Spearman’s correlation test. 
In order to test for differences between adjusted means, univari-
ate analysis incorporating covariate testing (one-way ANCOVA) 
was performed after logarithmic transformation of data. Positive 
predictive values (PPVs) and negative predictive values (NPVs) 
of the studied parameters were assessed using contingency tables 
and the Fisher’s exact test. A binary backward logistic regression 
model was used to determine whether elevated FVIII and VWF 
levels of different time points are independent predictors of poor 
functional outcomes at 90  days post-event. Adjustment of the 
models were based on the results of previous statistical analyses 
(Mann–Whitney U test, Fisher’s exact, or χ2 test), previous lit-
erature and methodological principles (dichotomized variables 
wherever possible). Results of the logistic regression analysis were 
expressed as odds ratio (OR) and 95% confidence interval (CI). 
A p-value of <0.05 was considered statistically significant.
resUlTs
study Population
During the study period, 131 consecutive AIS patients receiving 
intravenous rt-PA treatment were enrolled. Baseline demographic 
variables, main stroke characteristics and details of thrombolysis 
treatment are listed in Tables  1 and 2. In case of six patients, 
intravenous thrombolytic therapy was supplemented with 
intra-arterial thrombolysis using rt-PA according to standard 
protocol; the duration of thrombolysis and the final dose of rt-PA 
applied did not significantly differ for these patients. Median age 
of the patient cohort was 69 (IQR: 59–79) years, 60.3% were 
men. The most common cerebrovascular risk factor was arterial 
hypertension in this patient cohort (n =  100, 76.3%). Median 
time from symptom onset to treatment was 155 (IQR: 125–180) 
min. Median NIHSS before stroke treatment was 8 (IQR: 5–14). 
TaBle 2 | Stroke characteristics.
Variable
stroke severity on admission, n (%)
NIHSS 0–5 36 (27.5)
NIHSS 6–10 46 (35.1)
NIHSS 11–16 29 (22.1)
NIHSS >16 17 (13.0)
Undetermined 3 (2.3)
stroke etiology (TOasT), n (%)
Large artery atherosclerosis 49 (37.4)
Small vessel occlusion 13 (9.9)
Cardioembolic 27 (20.6)
Other/undetermined 42 (32.1)
imaging data
ASPECTS, median (IQR)
On admission 10 (9–10)
24 h after thrombolysis 9 (5–10)
Affected vessel territory, n (%)
MCA 82 (62.6)
ICA 11 (8.4)
MCA + ICA 10 (7.6)
VB 28 (21.4)
Level of occlusion, n (%)
No stenosis/occlusion 34 (26.0)
Stenosis 27 (20.6)
Occlusion 70 (53.4)
Outcomes, n (%)
Functional outcome at 7 days
Favorable outcome 49 (37.4)
No change 42 (32.1)
Unfavorable outcome 20 (15.3)
Functional outcome at 90 days
mRS 0–2 57 (43.5)
mRS 3–6 51 (38.9)
Undetermined 23 (17.6)
Intracranial hemorrhage (ECASS II)
aSICH 7 (5.3)
SICH 6 (4.6)
n, number of patients; IQR, interquartile range, NIHSS, National Institutes of Health 
Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; ASPECTS, 
Alberta Stroke Program Early Computed Tomography Score; MCA, middle cerebral 
artery; ICA, internal carotid artery; VB, vertebrobasilar territory; mRS, modified Rankin 
Scale; ECASS II, European Cooperative Acute Stroke Study II; aSICH, asymptomatic 
intracerebral hemorrhage; SICH, symptomatic intracerebral hemorrhage.
TaBle 1 | Study population.
Variable
Patients, n 131
Age, median (IQR) 69.0 (59.0–79.0)
Male, n (%) 79 (60.3)
cerebrovascular risk factors, n (%)
Arterial hypertension 100 (76.3)
Atrial fibrillation 35 (26.7)
Hyperlipidemia 81 (61.8)
Diabetes mellitus 39 (29.8)
Smoking
 Non-smoker 69 (52.7)
 Previous smoker 16 (12.2)
 Current smoker 31 (23.7)
 Undetermined 15 (11.5)
Previous stroke or Tia, n (%) 42 (32.1)
Thrombolysis treatment, median (iQr)
Time from symptom onset to treatment (min) 155 (125.0–180.0)
Duration of thrombolysis (min) 60 (60.0–65.0)
rt-PA dose (mg) 67.0 (58.0–80.8)
Medication at enrollment, n (%)
Antihypertensive therapy 93 (71.0)
 Angiotensin-converting enzyme inhibitor 60 (45.8)
 Alpha blocker 7 (5.3)
 Beta blocker 56 (42.8)
 Calcium channel blocker 30 (22.9)
 Diuretics 39 (29.8)
Antiplatelet druga 58 (44.3)
Anticoagulant drug 7 (5.3)
Lipid lowering therapy 38 (29.0)
Antidiabetic therapyb 16 (12.2)
laboratory measurements, median (iQr)
INR 0.98 (0.94–1.03)
APTT (s) 28.5 (26.1–32.1)
WBC (G/L) 7.59 (6.12–9.0)
Platelets (G/L) 207.5 (169.0–254.3)
Serum glucose (mmol/L) 6.5 (5.5–7.9)
hsCRP (mg/L) 3.06 (1.7–5.9)
Creatinine (μmol/L) 78.0 (64.0–97.0)
IQR, interquartile range; TIA, transient ischemic attack; rt-PA, recombinant tissue 
plasminogen activator; INR, international normalized ratio; APTT, activated partial 
thromboplastin time; WBC, white blood cell; hsCRP, high sensitivity CRP.
aAspirin or P2Y12 inhibitor treatment or both.
bInsulin therapy or oral antidiabetic drug therapy.
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According to the TOAST criteria, etiology of stroke was most 
commonly large vessel disease (n = 49, 37.4%), followed by 27 
(20.6%) patients with cardioembolic stroke. As detected by CTA 
on admission, 70 patients (53.4%) had a vessel occlusion, and 
27 patients (20.6%) stenosis. Poor functional outcome at 7 days 
post-event was observed in 20 cases (15.3%), while poor outcome 
at 90 days (mRS ≥ 3) was observed in case of 51 (38.9%) patients. 
Therapy-associated intracranial hemorrhage was detected in 13 
cases, of which 6 cases (4.6%) were symptomatic according to 
ECASS II. Mortality rates by day 7, 14, and day 90 post-event were 
3.8, 6.1, and 22.1%, respectively.
The effect of Thrombolysis on FViii 
activity and VWF antigen levels
The median and IQR values of FVIII activity and VWF antigen 
levels are shown at all investigated time points in Figures 1A,B, 
respectively. In the samples taken on admission, the median values 
of both hemostasis parameters were above the upper limit of the 
respective reference interval in the whole patient cohort (FVIII 
activity median: 188.0%, IQR: 153.0–242.0%, VWF antigen level 
median: 201.3%, IQR: 169.1–259.6%). FVIII activity dropped 
significantly in the samples obtained immediately after throm-
bolysis as compared to the initial values (median: 102.0%, IQR: 
62.0–155.5%, p <  0.001) and showed an increase 24  h after the 
event (median: 166%, IQR: 130.0–209.0%, p = 0.014) (Figure 1A). 
On the contrary, VWF levels increased steadily post-lysis (median 
VWF levels immediately after lysis: 229.1%, IQR: 157.6–293.3%, at 
24 h post-lysis: 231.6%, IQR: 176.8–284.8%, Friedman’s two-way 
ANOVA p = 0.002). Notably, VWF median and IQR values were 
above the upper limit of the reference interval at all investigated 
time points in the study cohort (Figure 1B).
Factor VIII activity and VWF antigen levels showed good cor-
relation on admission (r = 0.748, p < 0.001) (Figure 2A), but no 
significant correlation was found immediately after thrombolysis 
FigUre 2 | Correlation between factor VIII (FVIII) activity and von Willebrand factor (VWF) antigen levels before thrombolysis (r = 0.748, p < 0.001) (a), immediately 
after thrombolysis (r = 0.093, p = 0.299) (B), and 24 h after thrombolysis (r = 0.420, p < 0.001) (c).
FigUre 1 | The effect of thrombolytic therapy on factor VIII (FVIII) activity (a) and von Willebrand factor (VWF) antigen levels (B). Results are expressed as median 
values and interquartile ranges (whiskers) as measured from samples taken on admission, immediately after thrombolysis and 24 h after thrombolysis. Upper and 
lower limits of respective reference intervals are indicated with dashed lines (FVIII activity: 60–168%, VWF antigen levels: 50–160%). Statistical significance was 
assessed using Friedman’s two-way ANOVA with Dunn–Bonferroni post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001 as compared to values on admission.
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(r = 0.093, p = 0.299, Figure 2B), most probably due to plasmin-
mediated FVIII degradation. Fair correlation was observed 
between the two parameters in the samples obtained 24 h after 
thrombolysis (r = 0.420, p < 0.001, Figure 2C).
The association of FViii activity and VWF 
antigen levels with stroke severity
von Willebrand factor antigen levels were gradually and sig-
nificantly elevated in case of more severe AIS (NIHSS 6–16 and 
NIHSS >16) at all investigated time points, but no such signifi-
cant association was observed for FVIII activity levels (Table 3). 
The association between VWF antigen levels and stroke severity 
remained significant after adjustments for confounders (current 
smoking, hsCRP, age) in the statistical model.
The association of elevated VWF levels and more severe 
AIS was also proved as significantly higher VWF levels were 
found at all investigated time points in patients presenting with 
worse 24 h post-lysis CT scans (ASPECTS score 7–0) (Table 4). 
Similar association was observed for FVIII levels, except for 
the samples investigated immediately after lysis. Associations 
for VWF levels and FVIII activity remained significant after 
adjustments for confounders (current smoking, hsCRP, age) in 
the statistical model (Table  4). As CT scans on admission are 
not indicative of stroke severity and have less predictive values 
as the ASPECTS at 24 h post-lysis, it was not surprising that no 
significant association was found between the investigated hemo-
stasis parameters and the ASPECTS on admission (Table 4). No 
association was found between FVIII activity and VWF antigen 
levels at any time points and stroke subtypes according to TOAST 
criteria (data not shown). FVIII activity at 24  h post-lysis was 
significantly elevated in patients with vessel occlusion (median: 
175.0%, IQR: 151.5–227.0%) as compared to those with stenosis 
only (median: 137.0%, IQR: 98.5–175.0%) or without occlusion/
stenosis (median: 142.0%, IQR: 115.0–177.0%) (p = 0.001) (Table 
S1 in Supplementary Material), while such association was not 
observed for VWF levels.
elevated FViii activity and VWF antigen 
levels as Predictors of Thrombolysis 
Outcomes
Factor VIII activity and VWF antigen levels were not associated 
at any investigated time points with short-term therapy outcomes 
as assessed by the changes in NIHSS score by day 7 post-lysis 
(data not shown).
No association was found between FVIII activity or VWF anti-
gen levels at any investigated time points and therapy-associated 
ICH, except for higher VWF at 24 h post-lysis in patients present-
ing with SICH (median: 226.8%, IQR: 176.5–279.4% vs. median: 
347.5%, IQR: 263.3–372.1% for no bleeding or aSICH vs. SICH, 
p = 0.017) (Figure S1 in Supplementary Material).
TaBle 4 | FVIII activity and VWF antigen levels according to ASPECTS on admission and at 24 h after thrombolysis.
asPecTs on admission asPecTs 24 h after thrombolysis
10 (n = 59) 9–0 (n = 34) p-Value p-Value* 10–8 (n = 55) 7–0 (n = 38) p-Value p-Value*
FViii activity (%)
On admission 171.0 (139.0–206.0) 188.0 (168.5–262.3) 0.072 0.046 171.0 (135.0–192.0) 194.0 (168.0–299.5) 0.002 0.001
Immediately after 
thrombolysis
90.0 (38.8–147.3) 125.0 (79.0–165.0) 0.056 0.041 92.0 (55.5–147.5) 114.0 (66.0–177.0) 0.141 0.256
24 h after thrombolysis 166.0 (135.0–198.0) 178.0 (134.0–234.0) 0.290 0.171 156.0 (121.0–182.0) 198.0 (158.0–246.0) 0.001 <0.001
VWF antigen (%)
On admission 193.1 (161.6–246.2) 199.4 (173.4–257.1) 0.236 0.182 191.5 (161.6–231.7) 223.2 (175.1–268.6) 0.012 0.018
Immediately after 
thrombolysis
224.7 (152.9–284.4) 224.5 (171.7–295.9) 0.505 0.270 199.2 (146.3–261.8) 255.2 (200.6–326.3) 0.004 0.002
24 h after thrombolysis 225.5 (180.0–295.9) 242.8 (180.8–270.2) 0.816 0.783 197.8 (174.2–259.6) 257.4 (205.1–320.1) 0.003 0.017
ASPECTS, Alberta Stroke Program Early Computed Tomography Score; FVIII, factor VIII; VWF, von Willebrand factor.
Data are presented as median and interquartile range. Patients on admission were dichotomized as having none (ASPECTS = 10) vs. any (ASPECTS = 9–0) early ischemic signs, 
while patients at 24 h after thrombolysis were dichotomized as having mild/none (ASPECTS 10–8) vs. moderate/severe (ASPECTS 7–0) ischemic signs according to previous 
literature (26, 27). p-Value: statistical significance assessed using the Mann–Whitney U test. p-Value*: statistical significance assessed after adjustments for covariates (active 
smoking, hsCRP, age) in the statistical model (ANCOVA after logarithmic transformation of variables).
TaBle 3 | FVIII activity and VWF antigen levels according to stroke severity on admission.
stroke severity on admission
nihss 0–5 (n = 36) nihss 6–16 (n = 75) nihss > 16 (n = 17) p-Value p-Value*
FViii activity (%)
On admission 175.5 (145.0–209.3) 186.0 (155.0–238.0) 212.0 (165.5–352.0) 0.162 0.046
Immediately after thrombolysis 108.0 (47.0–148.0) 92.0 (70.0–152.0) 114.0 (51.5–201.0) 0.571 0.400
24 h after thrombolysis 159.0 (115.5–188.5) 162.0 (134.0–208.0) 172.0 (134.0–234.0) 0.292 0.163
VWF antigen (%)
On admission 189.6 (151.9–233.2) 199.6 (176.4–250.8) 247.8 (199.9–353.8) 0.013 0.013
Immediately after thrombolysis 172.2 (141.2–257.0) 229.2 (166.6–293.6) 276.8 (219.1–375.5) 0.008 0.011
24 h after thrombolysis 181.4 (156.9–246.8) 235.9 (188.3–292.7) 261.7 (192.4–366.8) 0.003 0.001
NIHSS, National Institutes of Health Stroke Scale; FVIII, factor VIII; VWF, von Willebrand factor.
Data are presented as median and interquartile range. Stroke severity of patients was classified according to previous literature (24, 25). p-Value: statistical significance assessed 
using the Kruskal–Wallis test. p-Value*: statistical significance assessed after adjustments for covariates (active smoking, hsCRP, age) in the statistical model (ANCOVA after 
logarithmic transformation of variables).
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Poor functional outcome (mRS ≥3) at 90 days post-event was 
associated with traditional risk factors including advanced age, 
increased NIHSS on admission, elevated hsCRP, and the presence 
of diabetes/diabetes treatment (Table 5). Moreover, as expected, 
ASPECTS at 24 h post-lysis and the level of vessel occlusion as 
detected by CTA was also indicative of the long-term outcome. 
Among the hemostasis parameters investigated at various time 
points, elevated FVIII activity 24 h post-lysis and elevated VWF 
antigen level measured immediately after lysis and 24  h after 
therapy showed significant association with poor outcomes 
(Table 5). Both parameters, as measured immediately post-lysis 
and 24 h post-lysis conferred a significant PPV and NPV for poor 
functional outcomes (highest PPV: VWF 24 after thrombolysis: 
0.83; 95% CI: 0.59–0.96, p = 0.009 and highest NPV: FVIII imme-
diately after thrombolysis: 0.73; 95% CI: 0.50–0.89, p = 0.009). 
 A binary backward logistic regression model including age, 
gender, elevated hsCRP, active smoking, diabetes mellitus, and 
NIHSS >5 on admission revealed that a FVIII activity and VWF 
antigen level above the upper limit of the reference interval (168 
and 160%, respectively) as measured immediately after lysis and 
24 h after thrombolysis significantly and independently increase 
the risk of unfavorable functional outcomes at 90 days (Table 6). 
In this model, FVIII activity and VWF antigen levels on admission 
did not prove to have an independent prognostic value regarding 
poor functional outcomes at 90 days, while elevated FVIII and 
VWF levels immediately after thrombolysis conferred an inde-
pendent OR: 7.09 (IQR: 1.77–28.38, p = 0.006) and OR: 6.31 (IQR: 
1.83–21.7, p = 0.003), respectively. Elevated levels of both factors 
24 h after lysis were also found to have a significant predictive 
value (OR: 4.67, IQR: 1.42–15.38, p = 0.011 for FVIII activity and 
OR: 19.02, IQR: 1.39–187.0, p = 0.012 for VWF antigen level). 
Besides these hemostasis parameters, only hsCRP >5.2 mg/L and 
NIHSS >5 on admission remained in the stepwise backwards 
regression analysis model as independent risk factors for poor 
outcomes at 90 days (OR: 4.85, 95% CI: 1.64–14.33, p = 0.004 and 
OR: 3.51, 95% CI: 1.17–10.57, p = 0.026, respectively).
DiscUssiOn
In this study, we examined the levels of FVIII and VWF during 
thrombolysis in 131 consecutive AIS patients and studied the 
relationship between the hemostasis factor levels and stroke 
TaBle 5 | Characteristics of patients according to functional outcomes at 
90 days following thrombolysis.
Variables mrs 0–2  
(n = 57)
mrs 3–6  
(n = 51)
p-Value
Age, median (IQR) 67.0 (58.0–76.0) 76.0 (62.0–83.0) 0.011
Male, n (%) 39 (68.4) 27 (52.9) 0.116
cerebrovascular risk factors, n (%)
Arterial hypertension 44 (77.2) 39 (76.5) 1.000
Atrial fibrillation 16 (28.1) 14 (27.5) 1.000
Hyperlipidemia 39 (68.4) 26 (51.0) 0.078
Diabetes mellitus 12 (21.1) 20 (39.2) 0.057
Previous stroke 21 (36.8) 14 (28.5) 0.412
Current smoker 12 (21.1) 13 (25.5) 0.817
stroke etiology, n (%)
Small vessel disease 8 (14.0) 3 (5.9)
Large vessel disease 17 (29.8) 21 (41.2) 0.238
Cardioembolic 13 (22.8) 10 (19.6)
nihss on admission, 
median (iQr)
6 (4–9) 14 (8–19) <0.001
imaging data
ASPECTS, median (IQR)
on admission 10 (9–10) 10 (9–10) 0.482
24 h after thrombolysis 9 (8–10) 7 (2–9) 0.001
Affected vessel territory, n (%)
MCA 33 (57.9) 33 (64.7)
ICA 4 (7.0) 3 (5.9) 0.093
MCA + ICA 2 (3.5) 7 (13.7)
VB 18 (31.6) 8 (15.7)
Level of occlusion, n (%)
No stenosis/occlusion 22 (38.6) 7 (13.7)
Stenosis 13 (22.8) 9 (17.6) 0.004
Occlusion 22 (38.6) 35 (68.6)
current drug use, n (%)
Antihypertensive therapy 43 (75.4) 36 (70.6) 0.821
Antiplatelet druga 26 (45.6) 25 (49.0) 0.846
Anticoagulant drug 2 (3.5) 4 (7.8) 0.425
Lipid lowering therapy 17 (29.8) 15 (29.4) 1.000
Antidiabetic therapyb 3 (5.3) 10 (19.61) 0.037
laboratory measurements, median (iQr)
INR 0.97 (0.94–1.02) 0.99 (0.96–1.06) 0.082
APTT (s) 27.9 (25.9–31.2) 28.6 (26.8–32.2) 0.117
WBC (G/L) 7.56 (6.21–8.87) 7.1 (6.06–9.03) 0.545
Platelets (G/L) 209.0 (179.5–240.7) 198.0 (162.0–261.0) 0.562
Serum glucose (mmol/L) 6.5 (5.45–7.40) 6.5 (5.5–8.03) 0.737
hsCRP (mg/L) 2.34 (1.02–4.12) 4.72 (1.80–10.11) 0.002
Creatinine (μmol/L) 77.0 (65.0–90.5) 81.0 (61.0–101.0) 0.735
FViii activity (%), median (iQr)
On admission 175.0 (142.0–218.5) 191.0 (161.0–274.0) 0.092
Immediately after thrombolysis 88.0 (44.5–149.0) 110.0 (66.0–185.0) 0.102
24 h after thrombolysis 153.0 (120.5–174.0) 176.0 (134.0–237.0) 0.018
VWF antigen (%), median (iQr)
On admission 193.1 (162.1–255.2) 214.0 (176.8–262.2) 0.092
Immediately after thrombolysis 204.1 (141.8–265.8) 254.8 (176.8–323.2) 0.011
24 h after thrombolysis 212.5 (160.0–251.6) 259.2 (191.0–315.1) 0.002
mRS, modified Rankin Scale; IQR, interquartile range; NIHSS, National Institutes of Health 
Stroke Scale; ASPECTS, Alberta Stroke Program Early Computed Tomography Score; 
MCA, middle cerebral artery; ICA, internal carotid artery; VB, vertebrobasilar territory; INR, 
international normalized ratio; APTT, activated partial thromboplastin time; WBC, white blood 
cell; hsCRP, high sensitivity CRP; FVIII, factor VIII; VWF, von Willebrand factor.
aAspirin or P2Y12 inhibitor treatment or both.
bInsulin therapy or oral antidiabetic drug therapy.
TaBle 6 | Association of FVIII activity and VWF antigen levels with poor 
functional outcome (mRS ≥ 3) at 90 days.
Odds ratio 95% confidence 
interval
p-Value
FViii activity >168%a
On admission 2.24 0.81–6.21 0.122
Immediately after thrombolysis 7.10 1.77–28.38 0.006
24 h after thrombolysis 4.67 1.42–15.38 0.011
VWF antigen >160%a
On admission 2.52 0.65–9.73 0.180
Immediately after thrombolysis 6.31 1.83–21.73 0.003
24 h after thrombolysis 19.02 1.94–186.99 0.012
mRS, modified Rankin Scale.
Backward multiple logistic regression model included age >75 years, gender, hsCRP 
>5.2 mg/L, active smoking, diabetes mellitus, NIHSS >5 on admission.
aThe upper limit of reference interval.
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characteristics and therapy outcomes. Only few papers are found 
in the literature studying the changes of certain hemostasis fac-
tors during the course of thrombolysis following ischemic stroke 
(28–31) and up to our knowledge, none of them studied the levels 
of FVIII and VWF comprehensively in this respect. It has been 
known for almost 40  years that in  vitro plasmin degrades and 
inactivates FVIII (32). Studies in animal models also suggested 
such effect of plasmin on FVIII (33); however, the in vivo effect 
of plasmin on FVIII in humans during the course of rt-PA-
induced thrombolysis, has not yet been characterized. Here, we 
showed that FVIII activity drops significantly immediately after 
thrombolysis as compared to levels measured on admission of 
patients. However, as the vast majority of patients had elevated 
FVIII levels on admission, this reduction, most probably due to 
plasmin-mediated degradation, did not reach a level that would 
suggest a potential risk for intracerebral hemorrhage. In fact, 
FVIII levels measured at any time points in this study were not 
associated with bleeding complications, which is in line with 
the results of studies in animal models (16). Opposite to FVIII 
activity, VWF antigen levels showed a rising tendency during the 
course of thrombolysis in our study. This, in theory might be due 
to two reasons. The first apparent reason is VWF degradation by 
plasmin, which has been shown before in vitro (34, 35). As the test 
we used for measuring VWF antigen levels contains polyclonal 
antibody against VWF, the degradation of the protein leads to 
an increased antigen level. In an early paper describing the time 
course of certain hemostasis factors in a few patients (n = 7) with 
AMI treated by rt-PA induced thrombolysis, it was shown that 
thrombolysis treatment resulted in the elevation of VWF antigen 
levels, most probably due to the proteolysis of VWF multimers. 
The degradation of VWF multimers has been speculated to be a 
potential causative factor for hemorrhagic complications in AMI 
patients treated with thrombolysis (11, 35). In our study, VWF 
antigen levels were found to be significantly higher at 24 h post-
lysis in patients with SICH as compared to the rest of the cohort, 
but due to the relatively low number of patients with SICH in this 
population (n = 6), this association should be confirmed by other 
studies. As for a second reason for the elevation of VWF antigen 
levels post-lysis, it is plausible that the increase is due to endothe-
lial damage caused by ischemic damage. Studies in AMI patients 
8Tóth et al. Levels of FVIII/VWF Predict Stroke Outcome
Frontiers in Neurology | www.frontiersin.org January 2018 | Volume 8 | Article 721
be incorporated into algorithms designed to select candidates for 
alternative approaches rather than rt-PA alone, e.g., mechanical 
thrombectomy or other pharmacological approaches (40–42). 
Moreover, studies on VWF in particular might prove even more 
useful in the future, as preclinical and clinical studies on inhibitors 
of VWF are promising and show a safe antithrombotic potential. 
When used in combination with tPA, VWF antagonists were able 
to prevent ongoing microvascular thrombus formation reducing 
stroke progression (7, 17). These findings are particularly inter-
esting in the light of our observations showing that VWF median 
and IQR values were constantly above the upper limit of the refer-
ence interval in the studied AIS population. Although drugs that 
target the inhibition of the action of VWF have not yet reached 
approval for the market (17), studies on FVIII/VWF levels during 
stroke and thrombolysis might provide useful descriptive data to 
understand the pathophysiology relevant to the potential clinical 
application of these inhibitors in the future in humans.
limitations
Our study has limitations. The sample size is limited, but in the 
light of other studies on AIS patients treated by thrombolysis it is 
considered representative. Due to the limited number of patients 
with SICH and with poor outcomes in this cohort, despite the 
significant associations found, results presented here need to be 
verified by larger studies.
We did not investigate AIS patients who were not suitable for 
rt-PA therapy. In theory, measuring FVIII/VWF levels of patients 
receiving and not receiving rt-PA and comparing the results with 
outcomes might seem useful. However, due to the important 
baseline differences between the two groups (e.g., the group not 
receiving rt-PA might be highly heterogeneous regarding time 
window from symptom onset, baseline coagulation screening 
tests, effective anticoagulation, age, etc.), which may significantly 
affect the results, such comparison might fail to support relevant 
conclusions.
The lack of advanced neuro-imaging (e.g., perfusion and col-
lateral circulation imaging) limits the application of this study.
Finally, as the study was designed to find potential biomarkers 
with predictive values for long-term outcomes following throm-
bolysis, we did not perform any functional characterization stud-
ies on the plasmin-mediated effect of FVIII and VWF proteins. 
In case of FVIII activity, we assumed, based on previous studies, 
that the reduction in activity levels as detected immediately 
after thrombolysis is due to plasmin-mediated degradation and 
did not perform any biochemical tests to prove this hypothesis. 
In case of VWF, functional activity tests, including ristocetin-
induced activity tests, collagen-binding assay, multimer testing, 
etc. were not measured in the patient population. Future stud-
ies are required to elucidate whether the qualitative changes of 
both proteins following stroke and thrombolysis would have any 
pathophysiological relevance and prognostic value.
cOnclUsiOn
Here, we report the changes in FVIII activity levels and VWF 
antigen levels during the course of thrombolysis in a cohort 
of consecutive AIS patients. Elevated FVIII activity and VWF 
suggested that thrombolysis induced by streptokinase is associ-
ated with an increase of VWF antigen levels due to endothelial 
damage as a result of oxidative stress caused by the thrombolytic 
agent (11, 15). Interestingly, in our study, VWF antigen levels 
showed an increase after thrombolysis only in patients with more 
severe stroke (NIHSS 6–16 and NIHSS >16 on admission), while 
in the group of patients with less severe stroke (NIHSS 0–5) this 
elevation was not seen, suggesting that at least in part endothelial 
dysfunction is likely to contribute to this finding.
Many studies have investigated the association between FVIII 
and/or VWF levels and the risk of cardiovascular or cerebro-
vascular events (8, 9, 12, 36). Despite few conflicting results, it 
has been well established that elevated FVIII and/or VWF levels 
predispose patients to AIS (8, 12). In line with our findings, 
most studies revealed that in the majority of tested patients with 
AIS, high FVIII and VWF levels were found; moreover, baseline 
stroke severity, as measured by the NIHSS score was associated 
with elevated FVIII and/or VWF levels (13, 37, 38). Furthermore, 
beyond these previously known results, here we describe a strong 
association between elevated FVIII/VWF levels during the course 
of thrombolysis and the ASPECT score in patients as assessed 
24  h post-lysis. The only non-significant association in this 
respect was for FVIII activity tested immediately after lysis, which 
was most probably due to plasmin-mediated degradation of the 
protein. The finding that the ASPECT score the day after stroke 
shows a strong association with the tested hemostasis parameters 
is of considerable interest, as it indicates a link between the 
investigated factors and stroke severity as verified by not only the 
NIHSS functional score but by imaging analysis as well. Similar 
findings on the relation of any hemostasis factors and the results 
of such imaging analysis is practically lacking in the literature as 
yet. Limited evidence is available on the possible association of 
FVIII/VWF levels with the etiology of stroke; moreover, reports 
are often discordant in this respect (8, 12, 39). Here, we could 
not find any association of FVIII/VWF levels with the subtype of 
stroke as classified by the TOAST criteria.
While the association between VWF levels and thrombolysis 
outcome following AMI has been studied before (15), surprisingly, 
similar data regarding ischemic stroke are much more limited. 
Here, we show that a FVIII activity and VWF antigen level above 
the upper limit of the reference interval, as measured immediately 
after or 24 h post-lysis, confer a significant, independent risk for 
poor functional outcomes at 90  days post-event. Our results 
indicate that both factors could be useful biomarkers having 
significant prognostic values on long-term outcomes, which 
might help with patient selection requiring alternative treatment 
post-lysis. At the same time, at least according to results of this 
cohort, pretreatment FVIII and VWF levels were not indicative 
of thrombolysis outcomes.
Although here we propose that our results have prognostic 
value in the studied patient cohort; nevertheless, we consider the 
relevance of our findings as potentially useful descriptive data, 
which might provide basis for future research, while its clinical 
relevance remains to be fully elucidated. In the era of mechani-
cal thrombectomy, the management of AIS faces new types of 
decision-making questions in the clinical practice. Useful bio-
markers with predictive values regarding poor outcomes might 
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antigen levels immediately after lysis and 24 h post-therapy were 
shown to have independent prognostic values regarding poor 
functional outcomes at 90 days.
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FigUre s1 | von Willebrand factor (VWF) antigen levels during the course of 
thrombolysis in patients with or without therapy-associated symptomatic 
intracranial hemorrhage (SICH). Results are expressed as median values (circles) 
and interquartile ranges (whiskers) as measured from samples taken on 
admission, immediately after thrombolysis and 24 h after thrombolysis. Open 
circles represent patients with SICH, solid circles represent patients with no 
bleeding or with asymptomatic intracranial hemorrhage (aSICH). Upper and lower 
limits of VWF reference interval (50–160%) are indicated with dashed lines. 
Statistical significance was assessed using Mann–Whitney’s U test. *p < 0.05 for 
SICH vs. no bleeding/aSICH.
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